Nuvalent, Inc. 4

Nuvalent Chief Development Officer Darlene Noci had all of her common shares, RSUs, PSUs, and stock options cashed out and cancelled at a $124.00 per share merger price in connection with GSK’s acquisition of Nuvalent.

On July 15, 2026, in connection with the closing of GSK’s acquisition of Nuvalent, Inc. at $124.00 per share, Chief Development Officer Darlene Noci’s equity awards were cashed out and cancelled pursuant to the Merger Agreement: 17,017 shares of Class A Common Stock were converted into cash at $124.00 per share, all 41,100 time-based RSUs and 14,350 performance stock units were cancelled for cash based on the $124.00 offer price (with 14,350 PSUs first vesting at the Merger), and all outstanding stock options covering an aggregate 181,153 shares with exercise prices ranging from $1.08 to $106.82 were cancelled for cash equal to the in-the-money value versus the $124.00 offer price. Following these merger-related settlements and cancellations, the reporting person no longer held any Nuvalent equity securities.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305072

Alert Tier

6